NTRB · XBRL financial data

NutriBand financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NTRB's year ends in late January)

In thousands of dollars	FY 2021Jan 31, 2021	FY 2022Jan 31, 2022	FY 2023Jan 31, 2023	FY 2024Jan 31, 2024	FY 2025Jan 31, 2025	FY 2026Jan 31, 2026
Revenue	944	1,422	2,080	2,085	2,140	2,037
Cost of revenue	582	918	1,329	1,223	1,396	1,470
Cost of goods and services sold	—	1,180	1,786	1,920	—	—
Gross profit	316	554	750	862	743	566
Research and development	—	411	982	1,960	3,119	1,891
Selling, general and administrative	2,957	4,023	3,916	3,774	4,314	6,993
Total operating expenses	2,912	6,615	—	5,734	11,028	8,884
Other operating income (expense)	56	(53)	—	—	—	—
Operating income (loss)	(2,596)	(6,111)	(4,475)	(4,872)	(10,285)	(8,318)
Interest income	—	—	—	17	192	111
Interest expense	9	118	8	76	21	23
Other income (expense)	(337)	(65)	(8)	(613)	—	—
Net income (loss)	(2,933)	(6,176)	(4,483)	(5,485)	(10,483)	(8,230)
Earnings per share, basic USD per share	(0.51)	(0.94)	(0.53)	(0.69)	(0.99)	(2.58)
Earnings per share, diluted USD per share	—	(0.80)	(0.53)	(0.69)	(0.99)	(2.58)
Weighted average shares, basic thousands of shares	—	7,933	8,460	7,954	10,607	11,641
Weighted average shares, diluted thousands of shares	5,771	6,800	8,460	7,954	10,607	11,641

Fiscal years (NTRB's year ends in late January)

In thousands of dollars	FY 2021Jan 31, 2021	FY 2022Jan 31, 2022	FY 2023Jan 31, 2023	FY 2024Jan 31, 2024	FY 2025Jan 31, 2025	FY 2026Jan 31, 2026
Cash and cash equivalents	152	4,892	1,985	493	4,312	4,575
Accounts receivable	109	71	113	149	74	118
Inventory	53	132	229	169	212	118
Total current assets	314	5,465	2,694	1,022	4,794	4,989
Property and equipment, net	1,077	979	898	775	695	567
Right-of-use asset	—	19	63	31	—	72
Goodwill	7,530	5,349	5,022	5,022	1,720	1,720
Total assets	9,927	12,740	9,456	7,517	7,470	7,548
Total current liabilities	2,569	779	749	999	983	784
Total deposits	—	250	250	—	—	—
Lease liability, non-current	—	—	34	—	—	48
Total liabilities	2,815	880	883	1,079	1,041	868
Accumulated deficit	(11,835)	(18,011)	(22,495)	(27,980)	(38,463)	(46,692)
Total stockholders' equity	7,112	11,859	8,573	6,438	6,429	6,679
Total liabilities and equity	9,927	12,740	9,456	7,517	7,470	7,548
Common shares outstanding (cover page) thousands of shares	6,356	7,821	7,833	10,970	11,154	12,156

Fiscal years (NTRB's year ends in late January)

In thousands of dollars	FY 2021Jan 31, 2021	FY 2022Jan 31, 2022	FY 2023Jan 31, 2023	FY 2024Jan 31, 2024	FY 2025Jan 31, 2025	FY 2026Jan 31, 2026
Net income (loss)	(2,933)	(6,176)	(4,483)	(5,485)	(10,483)	(8,230)
Stock-based compensation	2,005	365	732	500	1,409	2,634
Depreciation and amortization	160	309	330	288	—	—
Net cash from operating activities	(297)	(2,809)	(2,987)	(3,528)	(4,627)	(5,135)
Purchases of property and equipment	—	82	79	52	92	5
Net cash from investing activities	67	(82)	(79)	(52)	(92)	(5)
Proceeds from issuing common stock	515	583	—	—	2,554	5,306
Proceeds from issuing equity	—	—	—	—	8,407	—
Net cash from financing activities	372	7,631	160	2,087	8,537	5,403
Net change in cash	142	4,740	—	—	—	—

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
NutriBand	3,422	438	(585)*	12.2M	—	Q2 FY27 10-QJul 31, 2026
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Sintx Technologies	3,590	452	(2,767)*	6.7M	1.3 quarters	Q2 FY26 10-QJun 30, 2026
Vycor Medical	159	418	(4.8)*	33.4M	32.8 quarters	Q2 FY26 10-QJun 30, 2026
Harvard Apparatus Regenerative Technology	351	414	(569)*	17.6M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Cerenome	2,366	411	(7,132)*	7.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Family Office of America	637	533	149*	30.8M	—	Q2 FY26 10-QJun 30, 2026
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026
Femasys	1,444	332	(3,936)*	8.4M	0.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.